Silverblade
Posts: 1,636
Price: 9.75
No Opinion
Latest Director Purchase
Today 11:29
Fergus Fleming picked up a further 25K shares on Friday to add to the 80K he picked up as part of the placing. Now holds just under 700K shares (Latest RNS appears to have missed out his placing purchase). This adds to the recent market purchases made by James McCullough, Julian Baines, Catherine Coste, Howard Doran and Chris Scott. Whilst the purchases are all small, in combination they represent the first time I can remember coordinated stock purchases by company directors. I have added to my position here and am starting to feel more optimistic about 2025 than I have for while. ATB to all who regularly post here. SB |
Very positive interview |
Question answered in interview on Vox with JB. No need for another fund raise. Sales are going well and accelerating. |
They can't buy whilst in possession of endogenous inside information but they have let it be known they expect the new US Health agency leads under Trump to be favourable to their business so I guess they can buy based on that exogenous public information. |
BoD been buying everyday recently, so more Tr-1buys tonight? |
The JB effect! Should have bought more I suppose but the risk was looking ominous. I got no reply to my question about conflicting RNS and whether they do or do not need future funding. I guess they don’t actually know for sure. Seems like not in the next 12 months and by then they could be flying . Lot of uncertainties in USA , but if they want a healthier fitter society then Renx can help with that and reduce their costs. Same applies to Vrci. |
director buys |
Can’t argue with any of that but here’s the main issue . Aim and the uk are in the poop. No traders no interest in any share . Aim only ever worked on hype and there’s no hype so unfortunately no hope |
Ah! Yes, I see that in the RNS although couldn't see it in the full Annual Report.
The RNS says "Renalytix is funded and projected to deliver anticipated profitability in two years with no further funding requirements"
So, no further fundraises within two years IF their projections are correct.
Of course, they may well not be. And profitability maybe after EDITA or some other spurious expenses / costs.
I would say that going from 2024's $33.5m loss on turnover of $2.3m to profitability in two years is going to be a tall order.
Don't get me wrong, I would like them to - I hold.
Good to have Julian Baines back onboard. |
Renalytix have said that they "believe that the company will be able to achieve profitability in 2 years" and "raised enough money to secure the run through profitability."
As far as I can see, they don't explicitly rule another fund raise out and it would be foolish of them to do so. |
Sounds like a wild guess. Debt reduced by 80 percent, profitability within 2 years and no further cash raise. Interesting comments about Trump and Kennedy commitment to fighting kidney disease. |
I’m going to take a wild guess and say ….no |
UBS buy 5 percent the day audited results published and sell the lot the next day. That probably hit the share price for whatever purpose. Does this present another opportunity at 20 percent below placing? |
And now Cvi USA take 9.96 percent (33 million shares). You’d think the share price might have doubled but I guess this all under the table wink wink nudge nudge say no more broker to broker stuff. Should be update shortly |
Ruffer (we never loose money) in for 8.5 per cent. Mills steps down as EC chairman and Baines takes back his old position. Mills said all landmarks had been achieved. Just need to ratchet up sales. Keep the ball rolling after initial good reception from doctors. Update in a few days. Presumably Ruffer have some idea, not being ones to squander randomly |
Love the deramps coming in over the last few days. Oh look unicorn have bought a shed load of shares how about that! |
The product is either not required or just fluff and nonsense; I would suggest the latter. It appears to be an excel spreadsheet rather than AI. Given doctors run to what would help a patient and that everything in the US is covered by insurance ie of no cost to the patient, the fact that this is a dead company shows they had nothing to offer the well-being of those with kidney issues that could not be got cheaper, quicker or was already there. |
The sales just never arrived. I was fortunate to cash out on the way up, though some way short of the top if I remember correctly. I don't invest in pre-revenue companies any more, though I am happy in a conservative way to get in to early stage revenue growers that aren't yet covering costs. The growth has to be there though, that's the important thing. The selling here started in those first quarters where the commercial uptake just never occurred. |
Placing at slight premium. 9p |
Unfortunately this has looked like a lost cause for 2 years now, little more than a shell of a company at this point. Ive turned £2k into £20 and the only reason i still hold these is because I cant be bothered selling... |
The key numbers coming will be sales since Aug 1.
How many do we think are needed to demonstrate this is a viable business?
I think they need to get to a $50m run rate quite quickly which is a little over 4000 per month.
Other views? |
US stock was briefly up 50% in pre-market trading. Quite a spike on decent volume. |
Broker appointed today..more massive dilution coming |
Someone bought £16.73K at 16.08,WHY!? |
Register for real-time alerts, custom portfolio, and market movers
Hot Features
Premium
